Cargando…
Detection of autoantibodies against reactive oxygen species modified glutamic acid decarboxylase-65 in type 1 diabetes associated complications
BACKGROUND: Autoantibodies against glutamate decarboxylase-65 (GAD(65)Abs) are thought to be a major immunological tool involved in pathogenic autoimmunity development in various diseases. GAD(65)Abs are a sensitive and specific marker for type 1 diabetes (T1D). These autoantibodies can also be foun...
Autores principales: | Khan, Mohd Wajid Ali, Banga, Kamalpreet, Mashal, Subhash N, Khan, Wahid Ali |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063234/ https://www.ncbi.nlm.nih.gov/pubmed/21385406 http://dx.doi.org/10.1186/1471-2172-12-19 |
Ejemplares similares
-
Pathogenic Roles of Glutamic Acid Decarboxylase 65 Autoantibodies in Cerebellar Ataxias
por: Mitoma, Hiroshi, et al.
Publicado: (2017) -
Identification of a dominant epitope of glutamic acid decarboxylase (GAD-65) recognized by autoantibodies in stiff-man syndrome
Publicado: (1993) -
Discrepancy of glutamic acid decarboxylase 65 autoantibody results between RSR radioimmunoassay and enzyme‐linked immunosorbent assay in patients with type 1 diabetes is related to autoantibody affinity
por: Kawasaki, Eiji, et al.
Publicado: (2019) -
Epilepsy in patients with insulin-dependent diabetes and relation to glutamic acid decarboxylase 65
por: Mahmoud, Adel A., et al.
Publicado: (2020) -
α Cell dysfunction in islets from nondiabetic, glutamic acid decarboxylase autoantibody–positive individuals
por: Doliba, Nicolai M., et al.
Publicado: (2022)